Cidara Therapeutics Inc

Cidara Therapeutics — Investor Day (September 2021)

110 slides from Cidara Therapeutics's investor day presentation, Sep 21, 2021

  1. Slide 1: Cidara R&D Day Sept 21st 2021

    1 C I D A R A R & D D AY S E P T 2 1 s t 2 0 2 1

  2. Slide 2: Forward-Looking Statements

    2 F O R WA R D - LO O K I N G S TAT E M E N T S T h e s e s l i d e s c o n t a i n f o r w a r d - l o o k i n g s t a t e m e n t s w i t h i n t h e m e a n i n g o f t h e P r i v a t e S e c u r i t i e s L i t i g a t i o n R e f o r m A c t o f 1 9 9 5 . The words “believe,” “may,” “will,” “e

  3. Slide 3: Program Overview

    3 P R O G R A M O V E R V I E W : J E F F R E Y S T E I N , P H D , C E O Taylor Sandison, CMOClinical Program Update REZAFUNGIN Hematology Expert ID/Fungal Expert Mark Levis, Johns Hopkins Kieren Marr, Johns Hopkins Les Tari, CSO CLOUDBREAK Eric Simoes, Univ. of Colorado Commercial Update Paul Daru

  4. Slide 4: Cidara Investment Thesis

    4 C I D A R A I N V E S T M E N T T H E S I S L e a d i n g s c i e n c e o n l o n g - a c t i n g a n t i f u n g a l a n d a n t i v i r a l p r e v e n t i o n a n d t r e a t m e n t REZAFUNGIN 1st antifungal in 15 years for treatment and prophylaxis indications Treatment – Phase 3 Prophylaxis

  5. Slide 5: Up to $1.3B potential value from existing partnerships

    5 U P TO $ 1 . 3 B I N P OT E N T I A L VA LU E F R O M E X I S T I N G PA R T N E RS H I P S • $30M upfront • $9M equity investment • $42M in development support • $487M clin/reg/comm milestones • Double-digit royalties in the teens Program: Rezafungin | Rights: ex-US/Japan $568M P h a s e 2 d a t

  6. Slide 6: Rezafungin Update

    6 REZAFUNGIN UPDATE S E P T E M B E R 2 0 2 1

  7. Slide 7: Global antifungal market and unmet need

    7 Source: Global sales for Cancidas – IQVIA; Noxafil – 2018 Merck Annual Report. Antifungal market data from IQVIA, as of December 31, 2017. GLOBAL ANTIFUNGAL MARKET $ 4 . 2 B I L L I O N NO NEW CANDIDA TREATMENT NO NEW PROPHYLAXIS 1 5 Y E A R V O I D HIGH MORTALITY DRUG-DRUG INTERACTIONS C L E A R

  8. Slide 8: Rezafungin Clinical Program

    8 R E Z A F U N G I N C L I N I C A L P R O G R A M TAY LO R S A N D I S O N , M D C H I E F M E D I C A L O F F I C E R , C I D A R A

  9. Slide 9: Two pivotal studies for treatment and prophylaxis

    9 T W O P I V OTA L S T U D I E S F O R T R E AT M E N T A N D P R O P H Y L A X I S TARGET INDICATION Treatment of candidemia and invasive candidiasis Prophylaxis against Aspergillus, Candida & Pneumocystis in allogeneic blood and marrow transplant patients P H A S E 3 P R O P H Y L A X I S T R I A

  10. Slide 10: Two pivotal studies for treatment and prophylaxis

    10 T W O P I V OTA L S T U D I E S F O R T R E AT M E N T A N D P R O P H Y L A X I S P H A S E 3 T R E A T M E N T T R I A L 1 TARGET INDICATION OVERALL OBJECTIVE Treatment of candidemia and invasive candidiasis FDA: Day 30 All-cause mortality vs SOC Expect topline data by end of 2021 TRIAL SIZE 18

  11. Slide 11: STRIVE Phase 2 program overview

    11 S T R I V E P H A S E 2 P R O G R A M O V E RV I E W • The Intent-to-treat (ITT) population: all randomized subjects • The Safety population: all subjects who received any amount of study drug • The Microbiological Intent-to-treat population (mITT): all subjects in safety population who had docum

  12. Slide 12: Rezafungin Phase 2 efficacy and safety

    12 R E Z A F U N G I N P H A S E 2 M E T I T S E F F I C A C Y A N D S A F E T Y O B J E C T I V E S Not powered for non-inferiority Comparable efficacy and safety to 1st line agent Superior time to negative blood culture Trends to improved early outcomes 1. STRIVE Phase 2: CID September, 2020. 1

  13. Slide 13: Day 30 all-cause mortality post hoc analysis

    13 3 0 - D AY A L L C A U S E M O R TA L I T Y – P O S T H O C A N A LY S I S F R O M P H A S E 2 S U P E R I O R I T Y N O N - I N F E R I O R I T Y 0-20% 10%-10% F A V O R S R E Z A F U N G I N FA V O R S C A S P O F U N G I N ReSTORE Phase 3 trial endpoint requires upper limit of confidence inter

  14. Slide 14: STRIVE Phase 2 time to negative blood culture

    14 S T R I V E P H A S E 2 T I M E T O N E G AT I V E B L O O D C U LT U R E 1 , 2 P H A S E 2 : A D D I T I O N A L B E N E F I T S M AY B E D U E TO F R O N T - LO A D E D D O S I N G O n c e w e e k l y f r o n t - l o a d e d d o s e e r a d i c a t e d f u n g i e a r l i e r t h a n c a s p o

  15. Slide 15: Additional benefits may be due to front-loaded dosing

    15 0 5 10 15Days REZAFUNGIN 400/200 % Neg. Blood Culture1 % Overall Cure2 Average Days in ICU1 CASPOFUNGINRz Cf2 Rz Cf Rz Cf 5 ICU DAYS 28/38 1 DAY 5 DAYS 2 DAYS 27/50 31/36 32/49 34/46 34/61 % Neg. Blood Culture2 73.7 54.0 73.9 55.7 86.1 65.3 13 DAYS 18 DAYS n/N n/N n/N P H A S E 2 : A D D I T I O

  16. Slide 16: ReSTORE Phase 3 program overview

    16 Re S TO R E P H A S E 3 P R O G R A M O V E RV I E W • The Intent-to-treat (ITT) population: all randomized subjects • The Safety population: all subjects who received any amount of study drug • The Microbiological Intent-to-treat population (mITT): all subjects in safety population who had docum

  17. Slide 17: Rezafungin Treatment Prophylaxis

    17 Rezafungin Rezafungin — Treatment — Prophylaxis

  18. Slide 18: ReSPECT prophylaxis trial may enable new standard of care

    18 R e S P E C T P H A S E 3 P R O P H Y L A X I S T R I A L M AY E N A B L E N E W S TA N D A R D O F C A R E P H A S E 3 T R E A T M E N T T R I A L 1 TARGET INDICATION TRIAL SIZE Treatment of candidemia and invasive candidiasis 184 patients3 (20% noninferiority margin) FDA: Day 30 All-cause morta

  19. Slide 19: Rezafungin designed to simplify prophylaxis dosing regimen

    19 R E Z A F U N G I N : D E S I G N E D TO S I M P L I F Y P R O P H Y L A X I S D O S I N G R E G I M E N A n t i f u n g a l p r o p h y l a x i s i n a l l o g e n e i c b l o o d a n d m a r r o w t r a n s p l a n t s e t t i n g 1 , 2 SOC for Candida and Aspergillus Day 8070605040302010-10 0

  20. Slide 20: ReSPECT may enable rezafungin to replace 3 drugs

    20 Week 1 2 3 4 12 Azole placebo Bactrim placebo Rezafungin 5 13 Day 1 17 90 120 1° Endpoint: Fungal Free Survival at Day 902 Follow upREZAFUNGIN ARM (N=~300) 17Week 1 2 3 4 12 Azole1 Bactrim Rezafungin Placebo 5 13 Day 1 90 120 COMPARATOR ARM (N=~150) Dose Includes patients with: AML, MDS, ALL, CML

  21. Slide 21: Unmet need in prevention of invasive fungal disease

    21 U N M E T N E E D I N P R E V E N T I O N O F I N VA S I V E F U N G A L D I S E A S E I N C A N C E R A N D T R A N S P L A N T PAT I E N T S M A R K L E V I S , M D A N D K I E R E N M A R R , M D J O H N S H O P K I N S U N I V E R S I T Y

  22. Slide 22: Hematologist viewpoint: management of AML

    Hematologist Viewpoint - Setting up the problem Management of AML MARK LEVIS, MD P R O G R A M L E A D E R , H E M A T O L O G I C M A L I G N A N C I E S A N D B O N E M A R R O W T R A N S P L A N T P R O G R A M , S I D N E Y K I M M E L C O M P R E H E N S I V E C A N C E R C E N T E R P R O F E

  23. Slide 23: AML incidence and mortality rates

    AML Incidence and Mortality Rates 20,240 new cases/year • Compare with lung cancer: 235,760 cases/year 11,400 deaths/year • Compare with lung cancer: 131,880 deaths/year Source: CA CANCER J CLIN 2021; 71:7–33 AML in the US: AML at Hopkins: 23

  24. Slide 24: AML is frequently a medical emergency

    AML is frequently a medical emergency…  Patients routinely present with: o Low platelets, leading to risk of catastrophic bleeding o Low hemoglobin, causing physical exhaustion o Low white blood cells, leading to rapidly fatal infections  Best management is to quickly treat the disease into remiss

  25. Slide 25: AML at Johns Hopkins Kimmel Cancer Center

    AML at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins  180 patients admitted each year to the Adult Leukemia Service o All newly-diagnosed (typically transferred from an ER…) o Majority undergo immediate therapy • 50% intensive, 50% non-intensive o Hospital stay of 2-6 weeks • 130 a

  26. Slide 26: Typical AML patient treatment course

    Diagnosis, Transfer to leukemia service Months 0 1 2 3 4 5 6 7 8 9 Induction Consolidation Consolidation Bone marrow transplant “Induce” a remission The “Typical” AML patient treatment course 26

  27. Slide 27: What if someone doesn't get treated

    What if someone doesn’t get treated…? 27

  28. Slide 28: 7+3 intensive induction therapy for AML

     Cytarabine o 100 or 200 mg/m2/day CI for 7 days  Anthracycline o 45-90 mg/m2 dauno or 12 mg/m2 ida IVP Days 1-3  Day 14 marrow… o If aplasia (marrow < 5% cellularity), wait for recovery o If residual leukemia, give 5+2 starting Day 21. o If after counts are recovered and still residual leukemia,

  29. Slide 29: Azacitidine + venetoclax non-intensive induction

    Fast forward to present day… Azacitidine + venetoclax: A non-intensive induction Source: N Engl J Med 2020; 383:617-629 29

  30. Slide 30: Preventing invasive fungal infections: risks and needs

    ID & Hematologist Facing a team dilemma Preventing Invasive Fungal Infections: Risks and Needs KIEREN MARR MD MBA P RO F ES S O R O F M E D I C I N E , J O H N S H O P K I N S S C H O O L O F M E D I C I N E D I R EC TO R , T R A N S P L A N T A N D O N CO LO GY I N F EC T I O U S D I S EA S ES V I

  31. Slide 31: Antifungal prophylaxis needed

    Antifungal prophylaxis needed candidiasis, aspergillosis, PCP Source: Atkins and He. Infect Dis Clin N Am 33 (2019) Infectious risk of treatment regimens by disease 31 Antifungal prophylaxis needed candidiasis, aspergillosis, PCP

  32. Slide 32: AML patients benefit from posaconazole

    AML patients receiving intensive chemotherapy benefit from posaconazole Posaconazole versus Fluconazole or Itraconazole for AML patients Source: Cornely et al N Engl J Med 2007 356:348-59 32

  33. Slide 33: Venetoclax induction in AML

    Venetoclax induction in AML  Venetoclax-based induction is now used in at least 50% of AML cases  Venetoclax is metabolized by the liver P450 system (CYP3A4)  Other drugs inhibiting CYP3A4 will lead to higher levels of venetoclax, causing toxicity  But underdosing venetoclax may lead to treatmen

  34. Slide 34: Azoles: limited utility with new drugs

    Azoles: Limited utility with new drugs Drug Company Effect Recommendations with Azoles Ibrutinib (Imbruvica) J&J AbbVie ↑ Ibrutinib exposure 12-100% of original dose Idelalisib Zydelig) Gilead ↑ AUC Monitor for side effects Acalabrutinib (Calquence) AZ ↑ acalabrutinib exposure Avoid combo Imatinib (

  35. Slide 35: Back to the patient

    Diagnosis, Transfer to leukemia service Months 0 1 2 3 4 5 6 7 8 9 Induction Consolidation Consolidation Bone marrow transplant Currently – we’re giving IV echinocandins on and off during periods of neutropenia With diagnosed IFI – we have to hold or dose-reduce anti-AML therapy (bad outcomes) Back

  36. Slide 36: What do we need?

    What do we need?  Antifungal with activity against Candida and Aspergillus  Not cytochrome P450 metabolized (few or no drug interactions)  Able to administer o If daily, needs to be IV and oral o If longer half life, can be IV (weekly infusions enabled)  Few or no toxicities (a must for preventa

  37. Slide 37: Results of RezaHemeDDI study

    37 R E S U LT S O F ‘ R E Z A H E M E ’ D D I S T U D Y TAY LO R S A N D I S O N , M D C H I E F M E D I C A L O F F I C E R , C I D A R A

  38. Slide 38: No dose adjustment of venetoclax expected with rezafungin

    38 N O D O S E A D J U S T M E N T O F V E N E TO C L A X E X P E C T E D W I T H R E Z A F U N G I N 0 50 100 150 200 250 300 0 10 20 30 40 50 60 70 80 Venetoclax alone Venetoclax with rezafungin Time (hours) Venetoclax concentration over time Hematologists reduce dose of venetoclax up to 88% if co

  39. Slide 39: No dose adjustment of ibrutinib expected with rezafungin

    39 N O D O S E A D J U S T M E N T O F I B R U T I N I B E X P E C T E D W I T H R E Z A F U N G I N 0 30 60 90 0 10 20 30 40 50 60 Ibrutinib alone Ibrutinib with rezafungin M ea n co nc en tr at io n (n g/ m L) Time (hours) Ibrutinib concentration over time1 Hematologists reduce dose of ibrutinib u

  40. Slide 40: Rezafungin commercial value

    40 R E Z A F U N G I N C O M M E R C I A L V A L U E P A U L D A R U W A L A C H I E F O P E R A T I N G O F F I C E R , C I D A R A

  41. Slide 41: Azole DDI dilemma/opportunity and market potential

    41 Rezafungin Rezafungin Azole DDI Dilemma/Opportunity Market Potential

  42. Slide 42: The azole dilemma is both clinical and commercial

    42 T H E A Z O L E D I L E M M A I S B OT H C L I N I C A L A N D C O M M E R C I A L Contraindications with azoles often require dose reduction of oncology therapy by 50-88%1, to levels not well studied Pipeline 2 AML ALL CLL Phase 1 197 141 115 Phase 2 186 153 86 Phase 3 24 8 9 Dose reductions mea

  43. Slide 43: Two essential hematology drugs: Imbruvica and Venclexta

    43 T W O E S S E N T I A L H E M ATO LO GY D R U G S : I M B R U V I C A & V E N C L E X TA * Global Data (2020 – actuals; 2021-2027 – analyst consensus forecast) $- $3,000 $6,000 $9,000 $12,000 $15,000 $18,000 2020 2021 2022 2023 2024 2025 2026 2027 Actual and Forecast Global Sales ($M)* >$15B Venc

  44. Slide 44: Two essential hematology drugs: Imbruvica and Venclexta

    44 T W O E S S E N T I A L H E M ATO LO GY D R U G S : I M B R U V I C A & V E N C L E X TA * Global Data (2020 – actuals; 2021-2027 – analyst consensus forecast) $- $3,000 $6,000 $9,000 $12,000 $15,000 $18,000 2020 2021 2022 2023 2024 2025 2026 2027 Actual and Forecast Global Sales ($M)* >$15B Venc

  45. Slide 45: Azole DDI dilemma/opportunity and market potential

    45 Rezafungin Rezafungin Azole DDI Dilemma/Opportunity Market Potential

  46. Slide 46: Clear potential advantages of rezafungin

    46 T H E R E A R E C L E A R P OT E N T I A L A D VA N TA G E S O F R E Z A F U N G I N E A R LY D I S C H A R G E / O U T PAT I E N T P O T E N T I A L YES Reza O N C E W E E K LY / F R O N T L O A D E D D O S I N G YES Daily Echinocandins NO NO

  47. Slide 47: Current estimates assume ReSTORE meets 20% NI margin

    47 C U R R E N T E S T I M AT E S A S S U M E Re S TO R E M E E T S 2 0 % N I M A R G I N Revenue Time Candida Treatment Infectious Disease Focus BASE CASE: ReSTORE meets 20% NI margin

  48. Slide 48: Rezafungin targeted downstream for Candida treatment

    48 R E Z A F U N G I N TA R G E T E D D O W N S T R E A M F O R C A N D I D A T R E AT M E N T Inpatient (1.6M pts/1.9M treatments) Daily IV Candin Daily IV Candin Rezafungin 29K 1.5% share example 5th YEAR FORECAST Patient and market share examples provided here are based on internal management ass

  49. Slide 49: Rezafungin targeted downstream for Candida treatment

    49 R E Z A F U N G I N T A R G E T E D D O W N S T R E A M F O R C A N D I D A T R E A T M E N T Inpatient (1.6M pts/1.9M treatments) Daily IV Candin Daily IV Candin Rezafungin 29K 1.5% share example 5th YEAR FORECAST PATIENTS • Stable • Azole non-susceptible • Early discharge possible PAYOR • Medic

  50. Slide 50: Rezafungin targeted downstream for Candida treatment

    50 R E Z A F U N G I N T A R G E T E D D O W N S T R E A M F O R C A N D I D A T R E A T M E N T Inpatient (1.6M pts/1.9M treatments) Outpatient (640K pts) Daily IV Candin Rezafungin Rezafungin Daily IV Candin Rezafungin 29K 9K 16K 3.9% share example1.5% share example 36% continuation of RZF from in

  51. Slide 51: U.S. sample revenue build and key assumptions

    51 U . S . S A M P L E R E V E N U E B U I L D A N D K E Y A S S U M P T I O N S F O R R E Z A F U N G I N Overall Treatment Inpatient Outpatient • Launch Treatment: 1Q23 • Launch Prophylaxis: 1H24 • No serious warnings/precautions • 30-50 reps, 6-8MSLs, 5 account managers • Focus on high AF & high

  52. Slide 52: ReSTORE upsides enhance probability of faster uptake

    52 Re S TO R E U P S I D E S E N H A N C E P R O B A B I L I T Y O F FA S T E R U P TA K E Revenue Time Candida Treatment Infectious Disease Focus Upside Case ReSTORE ~ STRIVE (Shorter ICU stay) Upside Plus Case Superiority BASE CASE: ReSTORE meets 20% NI margin

  53. Slide 53: Clear potential advantages of rezafungin

    53 T H E R E A R E C L E A R P OT E N T I A L A D VA N TA G E S O F R E Z A F U N G I N Well-tolerated No DDIs Fluconazole Posaconazole S A F E T Y / T O L E R A B I L I T Y Daily IV administration Hepatic and renal precautions Significant DDIs C O V E R A G E / S P E C T R U M Candida, Aspergillus

  54. Slide 54: U.S. sample revenue build for rezafungin

    54 U. S . S A M P L E R E V E N U E B U I L D F O R R E Z A F U N G I N *Prophylaxis revenue includes potential for product use other than in the anticipated initial indication, not supported by Company promotion. Overall Treatment Inpatient Outpatient 331 743 101 202 92 191 5-Year ($M) 10-Year ($M)

  55. Slide 55: Other antifungals triangulate rezafungin market opportunity

    55 OT H E R A N T I F U N G A L S T R I A N G U L AT E R E Z A F U N G I N M A R K E T O P P O R T U N I T Y *Prophylaxis revenue includes potential for product use other than in the anticipated initial indication, not supported by Company promotion. Overall Treatment Inpatient Outpatient 331 743 10

  56. Slide 56: Cloudbreak Update

    56 CLOUDBREAK UPDATE S E P T E M B E R 2 0 2 1

  57. Slide 57: Cloudbreak has advantages over vaccines and treatments

    57 57 C LO U D B R E A K H A S A D VA N TA G E S O V E R VA C C I N E S A N D T R E AT M E N T S MODERNA Sept 9, R&D Day report COVID-19 and flu combination vaccine REGENERON Sept 15, Endpoints News $2.9B purchase of COVID-19 antibodies (3rd supply deal)

  58. Slide 58: Cloudbreak drug-Fc conjugates: a new class of drug

    58 C L O U D B R E A K D R U G - F c C O N J U G A T E S : A N E W C L A S S O F D R U G L E S T A R I , P h D C H I E F S C I E N T I F I C O F F I C E R , C I D A R A

  59. Slide 59: Cloudbreak combines an Fc moiety with potent antivirals

    59 C LO U D B R E A K ® C O M B I N E S A N Fc M O I E T Y W I T H P OT E N T A N T I V I R A L S Fc MOIETY SM TARGETING MOIETIES PEPTIDE FUSIONS Extends PK and recruits immune system Single or multiple types of small molecules with direct antiviral activity can be conjugated to the same Fc Multiple

  60. Slide 60: Cloudbreak is a new class of drug Fc conjugates

    60 C LO U D B R E A K ® I S A N E W C L A S S O F D R U G F C C O N J U G AT E S : “ D F C s ” Drug Fc Conjugate

  61. Slide 61: Unique advantages of drug-Fc-conjugates

    61 U N I Q U E A D VA N TA G E S O F D R U G - Fc - C O N J U G AT E S VIRUS ADVANTAGES OF DFCs • Multivalent binding increases potency • Engaging different targets on the same virus improves spectrum, decreases resistance • Enables a single DFC to target multiple viruses

  62. Slide 62: DFCs can be effective where current flu vaccines fall short

    62 D F C s C A N B E E F F E C T I V E I N T H O S E M I S S E D BY C U R R E N T F LU VA C C I N E S 1. DFC assessments are based on pre-clinical study results and estimates Universal protection: multiple viruses Potential to protect all high risk groups Potential for prevention and treatment Scale

  63. Slide 63: DFCs have potential advantages over antibodies

    63 D F C s H A V E P O T E N T I A L A D V A N T A G E S O V E R A N T I B O D I E S 1. DFC assessments are based on pre-clinical study results and estimates Able to target cryptic sites, small molecule binding pockets Able to modulate drug-Fc-ratio to increase potency Able to install 2 or more disc

  64. Slide 64: DFCs have potential advantages over small molecules

    64 D F C s H AV E P OT E N T I A L A D VA N TA G E S O V E R S M A L L M O L E C U L E S 1. DFC assessments are based on pre-clinical study results and estimates 2. CYP450s, metabolic enzymes Selectivity vs host targets (toxicity potential) Pharmacokinetic properties, DDIs Distribution to compartmen

  65. Slide 65: DFC development candidates targeting influenza

    65 Single dose / ̴3 months Wild-type Fc (full immune engagement) C D 3 7 7 C D 3 8 8 Single dose / ̴4-6 months Mutant Fc (attenuated immune engagement, improved PK, and extended duration of action) D F C D E V E LO P M E N T C A N D I D AT E S TA R G E T I N G I N F LU E N Z A These are the first ag

  66. Slide 66: DFCs have rapid distribution to lung

    66 66 D F C s H A V E R A P I D D I S T R I B U T I O N T O L U N G CD377 concentration in plasma and Epithelial Lining Fluid (ELF) after a single 20 mg/kg subcutaneous dose Plasma Lung ELF C D 3 7 7 I N F LU E N Z A P R O G R A M CD377 concentration in lung epithelial lining fluid is ~ 60% of that

  67. Slide 67: 28-day single-dose protection in mouse

    67 67 2 8 - D A Y , S I N G L E - D O S E P R O T E C T I O N I N M O U S E A/Hong Kong/1/68 H3N2 SC dose Infect Vehicle Levin et al, IDWeek 2020, Abstract 159. 5 BALB/c mice per cohort C D 3 7 7 I N F L U E N Z A P R O G R A M CD377 is fully protective for 28-days in a lethal influenza model with a

  68. Slide 68: DFCs show similar efficacy in immune competent and compromised mice

    68 5 mice per cohort. CD377 (SC) dosing was initiated 2 hours post-infection CD377 – 0.1mg/kg Vehicle CD377 – 0.1mg/kg Vehicle A/PR/8/1934 H1N1 Mouse treatment models BALB/c immune competent SCID immune deficient D F C s S H O W S I M I L A R E F F I C A C Y I N I M M U N E C O M P E T E N T A N D C

  69. Slide 69: Robust preclinical safety

    69 R O B U S T P R E C L I N I C A L S A F E T Y 1. Results of 14-day preclinical toxicity testing, CD377 THERAPEUTIC MARGIN 0 250000 500000 Primate Area under the curve (AUC) for maximum dose tested (hr*mg/mL) Predicted AUC required for efficacy in humans (hr*mg/mL) 95x Clinical Observations Hemato

  70. Slide 70: Unmet needs in respiratory viruses

    70 U N M E T N E E D S I N R E S P I R ATO R Y V I R U S E S E R I C S I M O E S , M D U N I V E R S I T Y O F C O LO R A D O

  71. Slide 71: Viral respiratory tract infections: prevention and treatment

    Viral Respiratory Tract infect ions I m p o r t a n c e a n d P r o s p e c t s fo r P r e v e n t i o n a n d Tr e a t m e n t Eric A.F. Simões, Professor of Pediatrics Section of Infectious Diseases, University of Colorado School of Medicine, and Childrenʼs Hospital Colorado Professor of Epidemiol

  72. Slide 72: Major viral respiratory pathogens

    72 M A J O R V I R A L R E S P I R A T O R Y P A T H O G E N S 72 SARS CoV2 Influenza Virus Respiratory Syncytial Virus Rhinovirus Parainfluenza viruses Human Metapneumovirus

  73. Slide 73: Major viral respiratory pathogens

    73 M A J O R V I R A L R E S P I R A T O R Y P A T H O G E N S 73 SARS CoV2 Influenza Virus Respiratory Syncytial Virus Rhinovirus Parainfluenza viruses Human Metapneumovirus

  74. Slide 74: SARS-CoV-2 global situation Sept 2021

    74 S A RS C O V - 2 : G LO B A L S I T UAT I O N - 1 3 S E P T 2 0 2 1 https://covid19.who.int/ Accessed 13 Sept 2021 224 Million Confirmed Cases, 4.63 Million confirmed Deaths 5.4 Billion Vaccine Doses Administered 74

  75. Slide 75: SARS-CoV-2 vaccines: good enough?

    75 S A R S C O V 2 V A C C I N E S : M A N Y , B U T A R E T H E Y G O O D E N O U G H ? Huang H-Yet al., Hum Vaccin Immunother2021;17:3276-3280 75 442 Clinical Trials on 185 vaccine Candidates

  76. Slide 76: Unmet needs in prevention and treatment persist

    76 D E S P I T E AVA I L A B I L I T Y O F VA C C I N E S , U N M E T N E E D S I N P R E V E N T I O N A N D T R E AT M E N T S T I L L P R E S I D E Prevention Issues Treatment Issues • While efficacious vaccines are available, universal global distribution is a real issue. • Vaccines protect agai

  77. Slide 77: Influenza: large pipeline of vaccine candidates

    77 I N F LU E N Z A – L A R G E P I P E L I N E O F VA C C I N E C A N D I D AT E S https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm Accessed 10 Sept 21 Universal Protection is Still Elusive 77

  78. Slide 78: Seasonal flu vaccine effectiveness is still sub-optimal

    78 S E A S O N A L F LU VA C C I N E E F F E C T I V E N E S S I S S T I L L S U B - O P T I M A L https://www.cdc.gov/flu/professionals/acip/2021-2022/acip-table.htm Accessed 10 Sept 21 … and even less effective for elderly and immune compromised 78

  79. Slide 79: Universal influenza prevention is still a major unmet need

    79 U N I V E RS A L I N F LU E N Z A P R E V E N T I O N I S S T I L L A M A J O R U N M E T N E E D Adult Subjects Pediatric Subjects Prevention Available Available Not very effective Not very effective Annual vaccination Annual vaccination through life Decreasing Efficacy Decreasing Efficacy 79

  80. Slide 80: RSV prevention: still a challenging problem

    80 RS V P R E V E N T I O N – S T I L L A C H A L L E N G I N G P R O B L E M VACCINES Still unproven and immunogenicity remains a problem mAbs Expensive, large dose (adults) Coverage/Resistance issues 80

  81. Slide 81: Unmet needs in RSV prevention and treatment

    81 U N M E T N E E D S I N R S V P R E V E N T I O N A N D T R E A T M E N T Prevention Issues Treatment Issues • For Infants Greatest burden of illness before 3 -6 months of age • Long acting monoclonal antibodies show promise but escape mutants are a possibility • Maternal immunization shows promi

  82. Slide 82: Expanding outside of ID: RSV, HIV, SARS-CoV-2

    82 RSV HIV SARS-CoV-2 Others — Improved potency — Broader coverage — Unique modality — Expanding outside of ID

  83. Slide 83: Influenza provides validation to address additional indications

    83 1 SC/IM dose/season Pan Flu Poor vaccines Pandemic Preparation FLU Janssen Pharmaceuticals I N F L U E N Z A P R O V I D E S VA L I D AT I O N TO A D D R E S S A D D I T I O N A L I N D I C AT I O N S RSV Seasonal Prevent | Treat 1 SC/IM dose/season No vaccine No Good Treatment HIV Chronic Mainta

  84. Slide 84: Expanding outside of ID: RSV, HIV, SARS-CoV-2

    84 RSV HIV SARS-CoV-2 Others — Improved potency — Broader coverage — Unique modality — Expanding outside of ID

  85. Slide 85: RSV cases on the rise in wake of surging COVID cases

    85 R S V C A S E S O N T H E R I S E I N T H E W A K E O F S U R G I N G C O V I D C A S E S AUGUST 14, 2021 • Leading cause of viral-induced infant mortality globally • No vaccines • Current therapies are suboptimal • New approaches clearly needed

  86. Slide 86: The power of single molecule DFC cocktails

    86 T H E P O W E R O F S I N G L E M O L E C U L E D F C C O C K TA I L S RVC-A RVC-B RVC-C 650 EC50 (nM) 0.2 EC50 (nM) <0.001 EC50 (nM) 4.0 EC50 (nM) RSV A2 Growth Inhibition Single molecule cocktail

  87. Slide 87: The power of optimizing small molecules

    87 T H E P O W E R O F O P T I M I Z I N G S M A L L M O L E C U L E S RSV A2 Growth Inhibition RVC-D 0.013 EC50 (nM) RVC-E 0.093 EC50 (nM) RVC-F 0.050 EC50 (nM) RVC-B 0.2 EC50 (nM)

  88. Slide 88: The power of optimizing small molecules

    88 T H E P O W E R O F O P T I M I Z I N G S M A L L M O L E C U L E S RSV A2 Growth Inhibition RVC-D 0.013 EC50 (nM) RVC-E 0.093 EC50 (nM) RVC-F 0.050 EC50 (nM) RVC-B 0.2 EC50 (nM) RSV Long RSV 9320 RSV 18357 EC50 (nM)

  89. Slide 89: The power of optimizing small molecules

    89 T H E P O W E R O F O P T I M I Z I N G S M A L L M O L E C U L E S RSV A2 Growth Inhibition RVC-D 0.013 EC50 (nM) RVC-E 0.093 EC50 (nM) RVC-F 0.050 EC50 (nM) RVC-B 0.2 EC50 (nM) RSV Long RSV 9320 RSV 18357 EC50 (nM) Next steps: single molecule cocktails with new SMs

  90. Slide 90: DFCs could address unmet need in adult populations

    90 D F C s C O U L D A D D R E S S A L A R G E U N M E T N E E D I N A D U L T P O P U L A T I O N S RSV FOR ADULTS, IV IS LIKELY THE ONLY OPTION WITH mAbs

  91. Slide 91: Expanding outside of ID: RSV, HIV, SARS-CoV-2

    91 RSV HIV SARS-CoV-2 Others — Improved potency — Broader coverage — Unique modality — Expanding outside of ID

  92. Slide 92: HIV treatments are moving to long-acting drugs

    92 H I V T R E AT M E N T S A R E M O V I N G TO LO N G - A C T I N G D R U G S DAILY ONE INJECTION PER MONTH1 1. Cabenuva package insert

  93. Slide 93: HIV single molecule cocktail DFCs are highly potent

    93 H I V S I N G L E M O L E C U L E C O C K T A I L D F C s A R E H I G H L Y P O T E N T SM CONJUGATE PEPTIDE FUSION DUAL HIV CONJUGATE HVC-A HVC-B2 HVC-C 1.. CEM-SS cells and HIV-1 IIIB live virus 2. CC50 > 10000 nM Optimized GP120 inhibitor conjugate Viral envelope binding peptide Single molecul

  94. Slide 94: HIV DFCs have potent broad-spectrum activity

    94 H I V D F C s H A V E P O T E N T B R O A D - S P E C T R U M A C T I V I T Y DUAL HIV CONJUGATE HVC-C TEMSAVIR CPE with hPBMCs - EC50 (nM) Single molecule cocktail CCR5 (UG/92/037) CXCR4/CCR5 (RW/92/009) CXCR4 (HT/92/599) CCR5 (US/921727) CCR5 (ZA/97/003) CXCR4/CCR5 (UG/92/001) MDR769 CXCR4/CCR5

  95. Slide 95: Global strain coverage with HIV cocktail

    95 G LO B A L S T R A I N C O V E R A G E W I T H S I N G L E M O L E C U L E H I V C O C K TA I L 1.. CEM-SS cells and HIV-1 IIIB live virus 2. CC50 > 10000 nM DUAL HIV CONJUGATE HVC-C 0.003 Single molecule cocktail Full activity in presence of human serum EC50 (nM)1 B B B C D AE A,C B,C B

  96. Slide 96: Expanding outside of ID: RSV, HIV, SARS-CoV-2

    96 RSV HIV SARS-CoV-2 Others — Superior potency — Broader coverage — Unique modality — Expanding outside of ID

  97. Slide 97: Current treatments have growing limitations

    97 C U R R E N T T R E AT M E N T S H AV E G R O W I N G L I M I TAT I O N S VACCINES Limited and waning coverage MONOCLONAL ANTIBODIES Poor tissue penetration Expensive Efficacy limited

  98. Slide 98: SARS DFC program objective: pan-coronavirus activity

    98 S A RS D F C P R O G R A M O B J E C T I V E : PA N - C O R O N AV I R U S A C T I V I T Y DFCs modularity enables: • Broader strain coverage • Targeting of multiple viruses

  99. Slide 99: First generation single-target SARS DFC

    99 1 s t G E N E R A T I O N S I N G L E - T A R G E T S A R S D F C * CC50 > 10000 nM (cytotoxicity measure, primate kidney cells) SVC-A* 29 EC50 (nM) Remdesivir ACTIVITY AGAINST CoV-OC43 147 EC50 (nM) NEXT GENERATION CORONAVIRUS DFCs • Testing DFCs with complimentary mechanisms to SVC-294 • Explor

  100. Slide 100: Next steps: single molecule cocktails

    100 FLU SARS RSV N E X T S T E P S : S I N G L E M O L E C U L E C O C K TA I L S TO TA R G E T M U LT I P L E R E S P I R ATO R Y V I R U S E S

  101. Slide 101: Expanding to oncology: a single molecule cocktail

    101 RSV HIV SARS-CoV-2 Oncology — Improved potency — Broader coverage — Unique modality — A single molecule cocktail

  102. Slide 102: Oncology faces similar challenges to viral disease

    102 O N C O L O G Y F A C E S S I M I L A R C H A L L E N G E S T O V I R A L D I S E A S E mAb/ADC LIMITATIONS • Toxicity/tolerability • Tissue/tumor penetration • Resistance/coverage • Expensive manufacturing SM LIMITATIONS • Toxicity/tolerability • Short half-life • Resistance

  103. Slide 103: DFCs uniquely positioned to address these limitations

    103 D F C s A R E U N I Q U E LY P O S I T I O N E D TO A D D R E S S T H E S E L I M I TAT I O N S Fc prolongs PK and improves tumor penetration over mAbs Small molecules fused to the Fc limit toxicity Multiple TMs enable a drug cocktail in a single molecule PENETRATION TOLERABILITY EFFICACY

  104. Slide 104: Fc fragments have improved tumor penetration vs mAbs

    104 Fc F R A G M E N T S H AV E I M P R O V E D T U M O R P E N E T R AT I O N V S m A b s 1. From Jäger et. al, https://doi.org/10.1021/acs.bioconjchem.1c00240 0 250µm MONOCLONAL ANTIBODY 150kDa 0 250µm Fc FRAGMENT1 50kDa Because DFCs are smaller, they should better penetrate tumors Bioconjugate Ch

  105. Slide 105: DFCs combine best attributes of mAbs and small molecules

    105 D F C s C O M B I N E T H E B E S T AT T R I B U T E S O F m A b s A N D S M A L L M O L E C U L E S Long Half-LifeShort Half-Life Low Tumor Penetration High Tumor Penetration Along with expected improvement in tumor penetration, DFCs extend half-life similar to mAbs DFCs Small molecules Monoclo

  106. Slide 106: 1st generation DFCs equipotent in vitro to competitor molecules

    106 1 S T G E N E R AT I O N D F C s : E Q U I P OT E N T I N - V I T R O TO C O M P E T I TO R M O L E C U L E S Discovery Preclinical IND-Enabling Phase 1 CBO−A IC50, (nM) CBO−B CBO−C CBO−D 2.6 2.6 1.2 4.7 SM DFC CONJUGATES Small Molecule IC50, (nM) 1.3 COMPETITOR PROGRAM All are structurally diff

  107. Slide 107: 1st generation DFCs equipotent in vitro to competitor molecules

    107 1 S T G E N E R A T I O N D F C s : E Q U I P O T E N T I N - V I T R O T O C O M P E T I T O R M O L E C U L E S Discovery Preclinical IND-Enabling Phase 1 CBO−A IC50, (nM) CBO−B CBO−C CBO−D 2.6 2.6 1.2 4.7 SM DFC CONJUGATES Small Molecule IC50, (nM) 1.3 COMPETITOR PROGRAM All are structurally

  108. Slide 108: Cloudbreak DFCs are a new class of drugs

    108 C L O U D B R E A K D F C s A R E A N E W C L A S S O F D R U G DFCs HAVE THE POTENTIAL to generate single molecule cocktails that can target multiple viruses or multiple pathways in oncology. 1. NEAR-TERM MILESTONES: IND filing CD388 (Influenza) at the end of 2021; initiation of Phase 1 trials

  109. Slide 109: Summary

    109 S U M M A R Y J E F F R E Y S T E I N , P h D C H I E F E X E C U T I V E O F F I C E R , C I D A R A

  110. Slide 110: Cidara Investment Thesis

    110 C I D A R A I N V E S T M E N T T H E S I S L e a d i n g s c i e n c e o n l o n g - a c t i n g p r e v e n t i o n s a n d t r e a t m e n t s REZAFUNGIN 1st antifungal in 15 years for treatment and prophylaxis indications Treatment – Phase 3 Prophylaxis – Phase 3 Validated with Deal ReSTORE

Cidara Therapeutics — Investor Day (September 2021) on 6ix